Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tambotatug pelitecan vs Chemotherapy in Metastatic Pancreatic Cancer
NCT07803783Phase 3Not yet recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Oct 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 3 trial of YL201 in pancreatic ductal adenocarcinoma (PDAC), sponsored by MediLink Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
YL201
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07803783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803783.